Epizyme Inc (EPZM) : Nea Management Company scooped up 1,111,111 additional shares in Epizyme Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 6,260,851 shares of Epizyme Inc which is valued at $56.3 Million.Epizyme Inc makes up approximately 3.71% of Nea Management Company’s portfolio.
Other Hedge Funds, Including , Foresite Capital Management Iii boosted its stake in EPZM in the latest quarter, The investment management firm added 15,126 additional shares and now holds a total of 476,777 shares of Epizyme Inc which is valued at $4.4 Million. Epizyme Inc makes up approx 3.40% of Foresite Capital Management Iii’s portfolio.Proshare Advisors boosted its stake in EPZM in the latest quarter, The investment management firm added 9,394 additional shares and now holds a total of 47,158 shares of Epizyme Inc which is valued at $439,984. Epizyme Inc makes up approx 0.01% of Proshare Advisors’s portfolio.Swiss National Bank boosted its stake in EPZM in the latest quarter, The investment management firm added 28,300 additional shares and now holds a total of 56,500 shares of Epizyme Inc which is valued at $527,145.
Epizyme Inc opened for trading at $9.07 and hit $9.72 on the upside on Monday, eventually ending the session at $9.58, with a gain of 6.44% or 0.58 points. The heightened volatility saw the trading volume jump to 2,40,010 shares. Company has a market cap of $548 M.
Many Wall Street Analysts have commented on Epizyme Inc. Shares were Reiterated by Mizuho on May 10, 2016 to “Buy” and Lowered the Price Target to $ 18 from a previous price target of $20 .Citigroup Initiated Epizyme Inc on Apr 5, 2016 to “Buy”, Price Target of the shares are set at $17.H.C. Wainwright Upgraded Epizyme Inc on Mar 14, 2016 to ” Buy”, Price Target of the shares are set at $25.
Epizyme Inc. is a clinical-stage biopharmaceutical company that discovers develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases or HMTs. The Company’s lead product candidate EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling and Phase I MLL-r pediatric patient trial enrolling.